Endothelin antagonism in pulmonary hypertension, heart failure, and beyond
- PMID: 15894792
- PMCID: PMC1768938
- DOI: 10.1136/hrt.2004.053991
Endothelin antagonism in pulmonary hypertension, heart failure, and beyond
Figures
References
-
- Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411–5. ▸ This is the original landmark report of the discovery of endothelin-1, including the isolation and sequencing of the peptide, identification of the gene sequence for its generation, and the pathway of production. This paper also highlights the vascular pharmacology and the pivotal role of ET-1 in vasoconstriction and hypertension. - PubMed
-
- Haynes WG, Webb DJ. Endothelin as a regulator of cardiovascular function in health and disease. J Hypertens 1998;16:1081–98. - PubMed
-
- Benigni A, Remuzzi G. Endothelin antagonists. Lancet 1999;353:133–8. ▸ A concise review on endothelin antagonists and their use in experimental and initial clinical studies. - PubMed
-
- Kedzierski RM, Yanagisawa M. Endothelin system: the double-edged sword in health and disease. Ann Rev Pharmacol Toxicol 2001;41:851–76. ▸ A comprehensive and updated review highlighting the involvement of endothelin-1 in the pathophysiology of cardiovascular disease. - PubMed
-
- Haynes WG, Webb DJ. Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet 1994;344:852–4. ▸ An important early clinical study showing the involvement of endothelin-1 in the maintenance of basal vascular tone. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical